Posted on: January 4, 2022
David Eberhard MD, Res ’95, PhD, has been appointed chief medical officer (CMO) of Inivata, a leader in liquid biopsy. Eberhard will oversee the clinical and strategic development of Inivata’s liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD).
Eberhard is a seasoned healthcare executive, bringing over 20 years’ experience in the research and development of oncology therapeutics, biomarkers, and diagnostics. He joins Inivata from Illumina, where he served as senior medical director for oncology and was responsible for providing clinical expertise, strategic vision, and leadership to build the corporate and public presence of a new and rapidly growing medical oncology group. Prior to this he held the role of senior director for oncology development at Genomic Health, where he provided strategic and tactical support to bring oncology mutation testing to market, with a focus on the company’s OncotypeSEQ, a liquid biopsy NGS gene mutation panel for solid tumors. Eberhard has been active as a consultant advising various biotech, pharma and VC clients on cancer drugs, diagnostic R&D and molecular pathology. He has also served as a pathologist in various lab-based roles, both within academia and industry, working on a variety of initiatives in oncology diagnostics, drug development and genomics.
Eberhard holds a Bachelor’s degree in Biology from the University of South Dakota and a MD / PhD in Pharmacology from the University of Michigan. He carried out his Postdoctoral Research Fellowship in Pathology and Pharmacology at the University of Virginia and holds an American Board of Pathology Certification in Anatomic Pathology and Neuropathology.